News

Ionis Pharmaceuticals Q2 2025 earnings highlight strong Tryngolza sales, increased 2025 revenue guidance, and upcoming Donidalorsen FDA approval.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2025.
While Ionis is currently conducting phase 2 clinical trials for the polycythemia vera treatment drug sapablursen in the US, Ono will lead clinical trials from phase 3 onwards and commercialize the ...